A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia

Study Number

4202824

Phase

I/II

Age Group

Adult

Principal Investigator

Eunice Wang

Purpose

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 (Part 1 \[Dose Escalation\] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.

Check your eligibility for this trial

Check now

Full Title

A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1)Inhibitor Bleximenib in Participants with Acute Leukemia

ClinicalTrials.Gov ID

NCT04811560

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.